MOGAT2 and obesity due to melanocortin 4 receptor deficiency: Transgenic and pharmacological studies in mice have demonstrated the beneficial effects of MOGAT2 inhibition as a therapy for several metabolic diseases, including obesity and insulin resistance [30,31].